Commodore Capital LP Cyma Bay Therapeutics, Inc. Transaction History

Commodore Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $21.8 Million - $35.6 Million	-3,713,500 Reduced 64.71%	2,025,000 $17.7 Million
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $882,533 - $1.16 Million	318,604 Added 5.88%	5,738,500 $17.8 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $4.04 Million - $5.75 Million	1,250,000 Added 29.98%	5,419,896 $18.3 Million
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $2.22 Million - $2.83 Million	640,431 Added 18.15%	4,169,896 $15.2 Million
Q2 2021 Aug 16, 2021	BUY	$3.94 - $4.92 $2.15 Million - $2.69 Million	545,952 Added 18.3%	3,529,465 $15.4 Million
Q1 2021 May 17, 2021	BUY	$4.23 - $6.55 $6.33 Million - $9.81 Million	1,497,406 Added 100.76%	2,983,513 $13.5 Million
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $8.52 Million - $13.4 Million	1,486,107 New	1,486,107 $8.53 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.